Research search

Reset all

34 matching records Analyze trends Open JSON Open API Download SQLite

Keyword search Author

Substances Psilocybin 3833 Psilocin 553

Date range quick select Last month Last year Last 5 years All time Custom range

BibTeX RIS CSV JSON SQLite

Executed search Sources: medRxiv 34 matching records are displayed.

Clear search

Latest Publications

Most recently published records currently stored in SQLite.

1-20

Last updated: Jul 2, 2026 22:01 UTC

Checking for newly published papers…

34 matching results

Navigating the chaos of psychedelic fMRI brain-entropy via multi-metric evaluations of acute psilocybin effects

A prominent theory of psychedelics is that they increase brain entropy. Thirteen studies have evaluated psychedelic effects on fMRI brain entropy; no findings have been replicated. Here we evaluated these metrics in an independent 28-participant healthy cohort with 121 pre- and post-psilocybin fMRI scans. We assessed relations between brain entropy and objec...

DOI 10.1101/2023.07.03.23292164

medRxiv 2023-07-02 McCulloch DE, Olsen AS, Ozenne B, Stenbaek DS, Armand S, Madsen MK, Knudsen GM, Fisher PM.

medRxiv PREPRINT (not peer reviewed) psilocybin Brain ImagingObservational Study Observational Study

Reduced brain responsiveness to emotional stimuli with escitalopram but not psilocybin therapy for depression

Psilocybin therapy is an emerging intervention for depression that may be at least as effective as standard first-line treatments i.e., Selective Serotonin Reuptake Inhibitors (SSRIs). Here we assess neural responses to emotional faces (fear, happy, and neutral) using Blood Oxygen-Level Dependent (BOLD) functional Magnetic Resonance Imaging (fMRI) in two gro...

DOI 10.1101/2023.05.29.23290667

medRxiv 2023-06-02 Wall MB, Demetriou L, Giribaldi B, Roseman L, Ertl N, Erritzoe D, Nutt DJ, Carhart-Harris RL.

medRxiv PREPRINT (not peer reviewed) psilocybin DepressionBrain ImagingReceptor PharmacologyBiomarkersAgingEmotional ProcessingDrug Interactions Other

Drug-drug interactions between classic psychedelics and psychoactive drugs: a systematic review

Classic psychedelics, lysergic acid diethylamide, psilocybin, mescaline and N,N-dimethyltryptamine, are potent psychoactive substances that have been studied for their physiological and psychological effects. However, our understanding of the potential interactions and outcomes of using these substances are used in combination with other psychoactive drugs i...

DOI 10.1101/2023.06.01.23290811

medRxiv 2023-05-31 Halman A, Kong G, Sarris J, Perkins D.

medRxiv PREPRINT (not peer reviewed) psilocybin Mechanism of ActionSystematic ReviewReview ArticleCase ReportDrug Interactions Systematic Review

Bridging the translational neuroscience gap: Development of the ‘shiftability’ paradigm and an exemplar protocol to capture psilocybin-elicited ‘shift’ in neurobiological mechanisms in autism

Clinical trials of pharmacological approaches targeting the core features of autism have failed. This is despite evidence from preclinical studies, genetics, post-mortem studies and correlational analyses linking peripheral and central markers of multiple candidate neurochemical systems to brain function in autism. Whilst this has in part been explained by t...

DOI 10.1101/2023.05.25.23290521

medRxiv 2023-05-25 Whelan TP, Daly E, Puts NA, Malievskaia E, Murphy DG, McAlonan GM.

medRxiv PREPRINT (not peer reviewed) psilocybin Mechanism of ActionReceptor PharmacologyBiomarkersClinical TrialAnimal Study Clinical Trial

A Phase I trial to inform clinical protocols for the safe administration of psilocybin-assisted psychotherapy

This Phase I trial aims to inform the development of safety protocols for psilocybin-assisted therapy. Psychedelics, including psilocybin, are increasingly being recognized as a successful treatment option for many mental health concerns. In order to decrease the risks associated with its clinical use, more data is required regarding its physiological effect...

DOI 10.1101/2023.04.12.23288325

medRxiv 2023-04-18 Bennett JN, Blough MD, Mitchell I, Galloway L, Bains R.

medRxiv PREPRINT (not peer reviewed) psilocybin Mystical ExperienceClinical TrialSafetyAdverse Events Clinical Trial

Psilocybin induces acute and persisting alterations in immune status and the stress response in healthy volunteers

Patients characterized by stress-related disorders such as depression display elevated circulating concentrations of pro-inflammatory cytokines and a hyperactive HPA axis. Psychedelics are demonstrating promising results in treatment of such disorders, however the mechanisms of their therapeutic effects are still unknown. To date the evidence of acute and pe...

DOI 10.1101/2022.10.31.22281688

medRxiv 2022-10-31 Mason N, Szabo A, Kuypers K, Mallaroni P, de la Torre Fornell R, Reckweg J, Tse D, Hutten N, Feilding A, Ramaekers J.

medRxiv PREPRINT (not peer reviewed) psilocybin DepressionMechanism of ActionBiomarkersHealthy VolunteersInflammationImmune Function Other

Neural mechanisms of psychedelic visual imagery

Visual alterations under classic psychedelics can include rich phenomenological accounts of eyes-closed imagery. Preclinical evidence suggests agonism of the 5-HT2A receptor may reduce synaptic gain to produce psychedelic-induced imagery. However, this has not been investigated in humans. To infer the directed connectivity changes to visual sensory connectiv...

DOI 10.1101/2022.09.07.22279700

medRxiv 2022-09-08 Stoliker D, Preller KH, Novelli L, Anticevic A, Egan GF, Vollenweider FX, Razi A.

medRxiv PREPRINT (not peer reviewed) psilocybin NeuroplasticityMechanism of ActionReceptor PharmacologyAnimal Study Animal Study

Effective connectivity of emotion and cognition under psilocybin

Classic psychedelics alter sense of self and patterns of self-related thought. These changes are hypothesised to underlie their therapeutic efficacy across internalising pathologies such as addiction and depression. Using resting-state functional MRI images from a randomised, double blinded, placebo-controlled clinical trial of 24 healthy adults under 0.215m...

DOI 10.1101/2022.09.06.22279626

medRxiv 2022-09-08 Stoliker D, Novelli L, Vollenweider FX, Egan GF, Preller KH, Razi A.

medRxiv PREPRINT (not peer reviewed) psilocybin DepressionAddictionDefault Mode NetworkBiomarkersEmotional ProcessingClinical Trial Clinical Trial

Psilocybin-induced reduction in chronic cluster headache attack frequency correlates with changes in hypothalamic functional connectivity

Chronic cluster headache (CCH) is an excruciating disorder of unknown pathophysiology, but hypothalamic dysfunction has been implicated. CCH is difficult to treat but on a case-basis, the psychedelic compound psilocybin is said to have beneficial effects. In this first-ever clinical trial ( NCT04280055 ), we evaluate in a small open-label study of CCH patien...

DOI 10.1101/2022.07.10.22277414

medRxiv 2022-07-09 Madsen MK, Petersen AS, Stenbæk DS, Sørensen IM, Schiønning H, Fjeld T, Nykjær CH, Ulv Larsen SM, Grzywacz M, Mathiesen T, Klausen IL, Overgaard-Hansen O, Brendstrup-Brix K, Linnet K, Johansen SS, Fisher PM, Jensen RH, Knudsen GM.

medRxiv PREPRINT (not peer reviewed) psilocybin Headache / MigraineBrain ImagingMechanism of ActionAgingClinical TrialSafety Clinical Trial

Persisting decreases in state and trait anxiety post-psilocybin: A naturalistic, observational study among retreat attendees

Anxiety disorders are the most common type of psychiatric disorders among Western countries. Evidence-based treatment modalities including pharmacological and cognitive-behavioral therapy result in relatively low response rates (average range: 51 - 58%). Historical and recent research suggests psychedelic drugs may be efficacious in alleviating anxiety-relat...

DOI 10.1101/2022.03.02.22271743

medRxiv 2022-03-01 Kiraga M, Kuypers KPC, Uthaug MV, Ramaekers J, Mason NL.

medRxiv PREPRINT (not peer reviewed) psilocybinpsilocin AnxietyMechanism of ActionPersonality ChangeObservational StudyHealthy Volunteers Observational Study

Psilocybin modulation of dynamic functional connectivity is associated with plasma psilocin and subjective effects

Background Psilocin, the neuroactive metabolite of psilocybin, is a serotonergic psychedelic that induces an acute altered state of consciousness, evokes lasting changes in mood and personality in healthy individuals, and has potential as an antidepressant treatment. Examining the acute effects of psilocin on resting-state dynamic functional connectivity imp...

DOI 10.1101/2021.12.17.21267992

medRxiv 2021-12-16 Olsen AS, Lykkebo-Valløe A, Ozenne B, Madsen MK, Stenbæk DS, Armand S, Mørup M, Ganz M, Knudsen GM, Fisher PM.

medRxiv PREPRINT (not peer reviewed) psilocybinpsilocin Brain ImagingConsciousnessAgingPersonality Change Other

Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies

ABSTRACT After a decades long period of investigational dormancy, there is renewed interest in employing psychedelics as treatments for mental illness and addiction. The academic journals, journal articles, academic institutions, and countries that have helped sustain clinical psychedelic research and the evolution of the literature on clinical studies of ps...

DOI 10.1101/2021.11.22.21266718

medRxiv 2021-11-23 Weleff J, Akiki TJ, Barnett BS.

medRxiv PREPRINT (not peer reviewed) psilocybin AddictionSafety Other

Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Review of the Research Literature and Published Case Studies

Growing evidence suggests that psilocybin, the active ingredient in hallucinogenic mushrooms, can rapidly and durably improve symptoms of depression, leading to recent breakthrough status designation by the FDA and legalization for mental health treatment in some jurisdictions. Depression in bipolar disorder is associated with significant morbidity and has f...

DOI 10.1101/2021.04.02.21254838

medRxiv 2021-04-06 Gard DE, Pleet MM, Bradley ER, Penn A, Gallenstein ML, Riley LS, DellaCrosse M, Garfinkle E, Michalak EE, Woolley JD.

medRxiv PREPRINT (not peer reviewed) psilocybin DepressionClinical TrialReview ArticleSafety Clinical Trial

Mapping Psilocybin-Assisted Therapies: A Scoping Review

We conducted a scoping review on psilocybin-assisted therapy for addiction, depression, anxiety and post-traumatic stress disorder. Psilocybin is a naturally-occurring tryptophan derivative found in species of mushroom with psycho-active properties. From 2022 records identified by database searching, 40 publications were included in the qualitative synthesis...

DOI 10.1101/2019.12.04.19013896

medRxiv 2019-12-11 Shore R, Ioudovski P, Goldie C, McKeown S, Dumont E, Queen’s University, Kingston On.

medRxiv PREPRINT (not peer reviewed) psilocybin DepressionAnxietyPTSDAddictionOCDEnd-of-Life DistressHeadache / MigraineClinical TrialRandomized Controlled TrialReview ArticleSafety Randomized Controlled Trial

Email alerts Open a focused sheet to subscribe broadly or narrow notifications by keyword, author, journal, topic, substance, and cited DOI.

Analytics Open a focused analytics workspace for timeline ranges, publication trends, top journals, topics, and authors.

Source	Count	Share	Status
Europe PMC	2,553	64.2%	Active
PubMed	302	7.6%	Active
ClinicalTrials.gov	287	7.2%	Active
OpenAlex	283	7.1%	Active
PsyArXiv	216	5.4%	Active
Crossref	157	4%	Active
bioRxiv	142	3.6%	Active

Psilocybin Research Publication Tracker

Research search

Latest Publications

Ethical Complexities and Best Practices in Informed Consent Processes for Psilocybin Services: A Qualitative Study

Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study

Meskalin / Mescaline

DMT und Ayahuasca / DMT and Ayahuasca

DMT und Ayahuasca / DMT and Ayahuasca

Neuroestimulantes naturales: de rituales ancestrales a terapias de vanguardia

Meskalin / Mescaline

Usos recreativos, medicinales y etnobotánicos de hongos alucinógenos: una revisión

Convergent biosynthesis of psilocybin in an ectomycorrhizal lineage: is the psychoactive end-product the selected trait?

Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms

Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review.

Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms

A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)

Psilocybin shows mixed results for patients with treatment-resistant depression

Single-dose psilocybin with CBT more effective than nicotine patch for smoking cessation

Revealing shortcomings in the assessment of psilocybin effects on OCD-related symptoms in preclinical and clinical studies: A systematic review

Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review.

Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders.

MFCC-DFT mapping of ligand recognition at the 5-HT2A receptor: energetic analysis of the interactions between serotonin, psychedelics, and antipsychotics.

Chemistry/structural biology of psychedelic drugs and their receptor(s).